NEW YORK – Oxgene and the Native Antigen Company announced Thursday they have agreed to partner to increase antigen manufacturing capabilities reagents for the development of SARS-CoV-2 diagnostics and vaccines.
The companies will use Oxgene's Adenoviral Protein Machine technology to deliver high-purity recombinant proteins. The technology uses an adenoviral expression vector and allows for scalable production of viral proteins in mammalian cells by tricking the adenovirus into making SARS-CoV-2 proteins.
The antigens are produced in mammalian cells to ensure full glycosylation and correct protein folding, the Native Antigen Company said. Diagnostics developed from these reagents will be able to confirm past infections and determine immunity levels, the company added.
The two Oxford, England-based companies said they're hoping to complete the first validation of the protein expression in the next month.